Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.
In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D003333:Coronaviridae Infections / Q000517:prevention & control*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000382:microbiology / Q000517:prevention & control*
D007370:Interferon Type I